Statement of Changes in Beneficial Ownership (4)
12 September 2019 - 6:29AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Davidson David |
2. Issuer Name and Ticker or Trading Symbol
bluebird bio, Inc.
[
BLUE
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer
|
(Last)
(First)
(Middle)
C/O BLUEBIRD BIO, INC., 60 BINNEY STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/9/2019
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
9/9/2019
|
|
M
|
|
3000
|
A
|
$50.51
|
34616
|
D
|
|
Common Stock
|
9/9/2019
|
|
S(1)
|
|
3000
|
D
|
$100.1133 (2)
|
31616
|
D
|
|
Common Stock
|
9/10/2019
|
|
M
|
|
2060
|
A
|
$50.51
|
33676
|
D
|
|
Common Stock
|
9/10/2019
|
|
S(1)
|
|
2060
|
D
|
$100.1573 (3)
|
31616
|
D
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
$50.51
|
9/9/2019
|
|
M
|
|
|
3000
|
(4)
|
3/1/2026
|
Common Stock
|
3000
|
$0.00
|
11685
|
D
|
|
Stock Option (right to buy)
|
$50.51
|
9/10/2019
|
|
M
|
|
|
2060
|
(4)
|
3/1/2026
|
Common Stock
|
2060
|
$0.00
|
9625
|
D
|
|
Explanation of Responses:
|
(1)
|
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
|
(2)
|
The range in prices for the transaction reported on this line was $100.00 to $100.36. The average weighted price was $100.1133. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
(3)
|
The range in prices for the transaction reported on this line was $100.00 to $100.47. The average weighted price was $100.1573. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
(4)
|
This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Davidson David C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE, MA 02142
|
|
|
Chief Medical Officer
|
|
Signatures
|
/s/ Jason F. Cole, Attorney-in-Fact
|
|
9/11/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2024 to May 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From May 2023 to May 2024
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.